These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 27382254)

  • 1. Position and enforcement practice of the People's Republic of China's pharmaceutical data exclusivity protection.
    Li N; Yu X; Pecht M
    Drug Des Devel Ther; 2016; 10():2015-20. PubMed ID: 27382254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raising the Barriers to Access to Medicines in the Developing World - The Relentless Push for Data Exclusivity.
    Diependaele L; Cockbain J; Sterckx S
    Dev World Bioeth; 2017 Apr; 17(1):11-21. PubMed ID: 26818105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the impact of intellectual property rules on access to medicines? A systematic review.
    Tenni B; Moir HVJ; Townsend B; Kilic B; Farrell AM; Keegel T; Gleeson D
    Global Health; 2022 Apr; 18(1):40. PubMed ID: 35428250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Exclusivity of data in drug registration files and Israel's international status with regard to intellectual property rights protection].
    Lipschitz Y; Tamir O; Shemer J
    Harefuah; 2004 Dec; 143(12):845-8, 912. PubMed ID: 15666700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RETHINKING THE ROLE OF CLINICAL TRIAL DATA IN INTERNATIONAL INTELLECTUAL PROPERTY LAW: THE CASE FOR A PUBLIC GOODS APPROACH.
    Reichman JH
    Marquette Intellect Prop Law Rev; 2009 Jan; 13(1):1-68. PubMed ID: 20431702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRIPS-plus and access to medicines in China.
    Chen J; Nie X; Yao P; Shi L
    J Public Health Policy; 2013 May; 34(2):226-38. PubMed ID: 23552834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand.
    Supakankunti S; Janjaroen WS; Tangphao O; Ratanawijitrasin S; Kraipornsak P; Pradithavanij P
    Bull World Health Organ; 2001; 79(5):461-70. PubMed ID: 11417042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of the legal regime of intellectual property protection in the pharmaceutical market.
    Pashkov VM; Golovanova IA; Olefir AA
    Wiad Lek; 2016; 69(3 pt 2):582-586. PubMed ID: 27717949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protecting the rights of producers original medicines.
    Pashkov V; Kotvitska A; Noha P
    Wiad Lek; 2017; 70(4):834-837. PubMed ID: 29064813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The trends and constructive ambiguity in international agreements on intellectual property and pharmaceutical affairs: Implications for domestic legislations in low- and middle-income countries.
    Son KB; Lee TJ
    Glob Public Health; 2018 Sep; 13(9):1169-1178. PubMed ID: 28585477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intellectual property rights and right of access to medicines].
    Velásquez G
    Med Trop (Mars); 2006 Dec; 66(6):526-8. PubMed ID: 17286013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the trade-related aspects of intellectual property rights (TRIPS) agreement on India as a supplier of generic antiretrovirals.
    Babovic S; Wasan KM
    J Pharm Sci; 2011 Mar; 100(3):816-21. PubMed ID: 20740678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of the legal regime of intellectual property protection in the pharmaceutical market.
    Pashkov VM; Golovanova IA; Olefir AA
    Wiad Lek; 2016; 69(3 pt 2):582-586. PubMed ID: 28478430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario.
    Grootendorst P; Shim M; Falconi A; Robinson T; Lexchin J
    Int J Health Serv; 2018 Oct; 48(4):702-715. PubMed ID: 30040005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical Insurance Information Systems in China: Mixed Methods Study.
    Li Y; Lu C; Liu Y
    JMIR Med Inform; 2020 Sep; 8(9):e18780. PubMed ID: 32673209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Research on the pharmaceutical intellectual property protection and supervision of pharmacy administration.
    Xu Z; Chen W
    Pak J Pharm Sci; 2017 May; 30(3(Special)):1081-1087. PubMed ID: 28671085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intellectual property protection for traditional medical knowledge in China's context: a round peg in a square hole?
    Xia N
    Med Law Rev; 2023 Aug; 31(3):358-390. PubMed ID: 37018625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trade, TRIPS, and pharmaceuticals.
    Smith RD; Correa C; Oh C
    Lancet; 2009 Feb; 373(9664):684-91. PubMed ID: 19167054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unfair competition under the TRIPS agreement: protection of data submitted for the registration of pharmaceuticals.
    Correa CM
    Chic J Int Law; 2002; 3(1):69-85. PubMed ID: 15709300
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.